CD274 and non-small cell lung carcinoma: This meta-analysis has included the highest number of trials studying the efficacy and safety of first-line PD-1/PD-L1 inhibitor in combination with CTLA-4 inhibitor in the treatment of patients with advanced non-small cell lung cancer, to the best of our knowledge.